A phase 1 study of patient-derived multi-tumor associated antigen specific t cells (MT-601) administered to patients with metastatic pancreatic cancer following frontline folfirinox
Active Project Grant Awarded Last action
- Award ID
- R44CA295168
- Recipient
-
Marker Therapeutics Inc. UEI CK3KR85CSP23
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,348,550
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 54% complete
- Originally
- Place of performance
- Houston, TX 77021, USA
Award details come from USAspending.gov.
Description
- Abstract
- Pancreatic cancer (PC) is an orphan disease with a 5-year relative survival of 11.5% and relative survival for metastatic PC of only 3.1%. Although surgical resection provides the best curative option, 200 patients with various cancer types. Therefore, marker therapeutics proposes to use MT-601, an improved mtaa-specific t cell product for PC in order to improve patient outcomes. Combining MT-601 with front-line folfirinox chemotherapy may overcome current limitations of immunotherapy in PC. This grant proposes a phase 1, open-label study to evaluate safety and efficacy of MT-601 combined with front- line chemotherapy in metastatic PC patients. Specific aim 1 assesses primary and secondary safety and efficacy outcomes in PC patients treated with front-line chemotherapy (folfirinox) in combination with MT- 601. Specific aim 2 will correlate biological characteristics in the product profile with clinical safety and efficacy outcomes. Successful completion of this grant will provide clinical proof of concept for MT-601 as a treatment for PC patients and support future clinical trials leading to future BLA filing and commercial approval of MT-601.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $674,275 | |
| Original award | $674,275 |
Quick answers
Who received award R44CA295168?
R44CA295168 was awarded to Marker Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2024.
How much is award R44CA295168 worth?
$1,348,550 has been obligated on R44CA295168.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award